Sugi Predict

Sugi Predict / Targets / BRDT

BRDT

Bromodomain testis-specific protein · Q58F21 · BRDT on Sugi Atlas →

48,100 patent compounds predicted against BRDT, 37,933 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL375839 SCHEMBL375839 0.81 4/20
SCHEMBL370550 SCHEMBL370550 0.56 4/20
SCHEMBL270240 SCHEMBL270240 0.55 4/20
SCHEMBL270236 SCHEMBL270236 0.54 4/20
SCHEMBL270237 SCHEMBL270237 0.50 4/20
SCHEMBL271567 SCHEMBL271567 0.47 4/20
SCHEMBL348840 SCHEMBL348840 0.47 4/20
SCHEMBL347749 SCHEMBL347749 0.43 4/20
Fedratinib Fedratinib (SCHEMBL263741) 1.00 3/20
Bi-2536 Bi-2536 (SCHEMBL372489) 1.00 3/20
SCHEMBL376236 SCHEMBL376236 0.88 3/20
SCHEMBL375825 SCHEMBL375825 0.83 3/20
SCHEMBL376040 SCHEMBL376040 0.83 3/20
SCHEMBL265332 SCHEMBL265332 0.82 3/20
SCHEMBL376093 SCHEMBL376093 0.81 3/20
SCHEMBL376152 SCHEMBL376152 0.81 3/20
SCHEMBL376142 SCHEMBL376142 0.79 3/20
SCHEMBL376263 SCHEMBL376263 0.78 3/20
SCHEMBL376178 SCHEMBL376178 0.78 3/20
SCHEMBL376100 SCHEMBL376100 0.77 3/20

Clinical trials — most relevant to BRDT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue PHASE2/PHASE3COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies PHASE1/PHASE2WITHDRAWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Utilizing A Genomic Sig for BRCAness to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
Cause of Familial Testicular Cancer nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease nanRECRUITING
Sperm Epigenome in Hodgkin Lymphoma nanNOT_YET_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRDT binder may also engage these)

ProteinNameSimilarity
Q4R8Y1 — 1.000 Q4R8Y1 →
A6QP06 — 0.993 A6QP06 →
F7DRV9 — 0.993 F7DRV9 →
F1QW93 — 0.992 F1QW93 →
D4A7T3 — 0.992 D4A7T3 →
Q5HZN1 — 0.992 Q5HZN1 →
Q91Y44 — 0.991 Q91Y44 →
Q9NQW6 — 0.991 Q9NQW6 →
P97868 — 0.991 P97868 →
BMP2K BMP-2-inducible protein kinase 0.991 landscape →
Q16649 — 0.990 Q16649 →
Q8WML3 — 0.990 Q8WML3 →
Q8C0C0 — 0.990 Q8C0C0 →
P46200 — 0.990 P46200 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.989 landscape →
Q76FK4 — 0.989 Q76FK4 →
Q8NDI1 — 0.989 Q8NDI1 →
Q5HYM0 — 0.989 Q5HYM0 →
Q8RWK8 — 0.989 Q8RWK8 →
Q14966 — 0.989 Q14966 →
Q08639 — 0.988 Q08639 →
Q8QGQ8 — 0.988 Q8QGQ8 →
B2GUY1 — 0.988 B2GUY1 →
Q3T8J9 — 0.988 Q3T8J9 →
P61406 — 0.988 P61406 →
ZMYND8 MYND-type zinc finger-containing chromatin reader ZMYND8 0.988 landscape →
TFDP2 Transcription factor Dp-2 0.988 landscape →
Q9JJN2 — 0.988 Q9JJN2 →
P62292 — 0.988 P62292 →
Q7YZA2 — 0.988 Q7YZA2 →